← All trials
NCT06900140
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 2, 2025
- Primary completion
- Aug 31, 2025
- Completion date
- Oct 31, 2025
- First posted
- Mar 28, 2025
- Last posted
- Jun 6, 2025
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lakeridge Health Science CenterLead sponsor
- Lakeridge Health Science CenterOfficial
- Lakeridge Health Science CenterSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.